0.45
+1.70%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gelteq
Its shares trade under the ticker GELS. It has been listed since 29 October 2024. In the fiscal year to 30 June 2025, it reported revenue of A$165,645 and a net loss of A$6.6m. At that date it held total assets of A$21.5m and shareholders' equity of A$15.8m.
Gelteq Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2024-10-29. Gelteq Limited is an Australia-based clinical and science-based company. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Oct 2024
- Website
- gelteq.com ↗
- Head office
- LEVEL 4, SOUTH MELBOURNE VIC
- Incorporated in
- C3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Simon SzewachExecutive Chairman of the Board, since 2021
- Mr. Nathan GivoniChief Executive Officer, Executive Director
- Mr. Anthony PantherChief Financial Officer
- The Hon. Philip DalidakisIndependent Non-Executive Director
- Prof. David MortonIndependent Non-Executive Director
- Mr. Jeffrey OlyniecIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gelteq Ltd operates in the Pharmaceuticals industry with a focus on white-label gel-based delivery solutions in Australia.
- Gelteq Limited offers end-to-end development services for prescription drugs and nutraceuticals in Melbourne.
- Gelteq's product suite spans five core verticals including pet care, sports, and pharmaceuticals.
Weaknesses
- Gelteq Ltd's IPO on 29 October 2024 marks its first public listing as a new company.
- Gelteq's business model relies on white-label formulations without direct consumer branding.
- Gelteq's market presence is limited to Australia with no international expansion mentioned.
Opportunities
- Gelteq can expand its pet care vertical within the Australian market for nutraceuticals.
- Gelteq's OTC and pharmaceutical verticals present growth opportunities in the Health Care sector.
- Gelteq's white-label formulations offer potential for partnerships with global pharmaceutical companies.
Threats
- Gelteq faces competition from established pharmaceutical companies in Australia.
- Gelteq's reliance on white-label solutions may limit brand recognition in the market.
- Gelteq's business is vulnerable to regulatory changes in the Australian Pharmaceuticals industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.